UBS O'Connor’s Kalaris Therapeutics KLRS Stock Holding History

UBS O'Connor’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,000	Closed	-$495K	–	618
2023 Q3	$495K	Buy	10,000 +2,609	+35%	+$178K	0.01%	402
2023 Q2	$578K	Buy	+7,391	New	+$703K	0.01%	432

Other funds holding KLRS

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

UBS O'Connor's KLRS Position: Q4 2023 in Review

UBS O'Connor sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 10,000 shares — an estimated $495K sold.

UBS O'Connor first reported a position in KLRS in Q2 2023 and held it in 2 quarters. The position peaked at $578K in Q2 2023. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

UBS O'Connor reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 10,000 Kalaris Therapeutics shares in Q4 2023, an estimated $495K.
UBS O'Connor first reported a position in Kalaris Therapeutics in Q2 2023 and held it in 2 quarters.
UBS O'Connor's Kalaris Therapeutics position peaked at $578K in Q2 2023.
81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.